Daxor Corporation Announces New Data on Blood Volume Analysis from Duke and Yale Universities Presented at THT 2025
Rhea-AI Summary
Daxor (DXR) announced new research findings from Duke University Medical Center and Yale School of Medicine presented at the Technology and Heart Failure Therapeutics Conference (THT) in February 2025. The studies focus on the company's Blood Volume Analysis (BVA) technology.
The Duke study revealed no correlation between pulmonary artery pressure readings and actual blood volume measured by BVA, challenging industry assumptions about pressure monitoring as a proxy for volume measurement in heart failure care.
The Yale study, conducted over 5 years, examined diuretic mechanism of action using BVA, demonstrating the technology's accuracy in detecting volume shifts. The research provided new insights into the fluid removal process and highlighted BVA's potential to improve treatment for millions of patients on diuretic therapy.
Positive
- BVA technology demonstrated superior accuracy compared to traditional pulmonary artery pressure monitoring
- Research validates BVA as the gold standard for fluid status assessment
- Studies from prestigious institutions (Duke and Yale) support BVA's clinical utility
Negative
- Research findings suggest current monitoring devices using proxies like weight or pressure have substantial limitations
News Market Reaction – DXR
In the trading session that priced this news, DXR gained 0.14%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Two Groundbreaking Studies on Fluid Management: Pulmonary Artery Pressure Monitoring Falls Short, New Diuretic Insights Emerge
Oak Ridge, TN, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces groundbreaking new studies from Duke University Medical Center and Yale School of Medicine, presented at the Technology and Heart Failure Therapeutics Conference (THT). Held from February 11-13, 2025, at the Omni Boston Hotel at the Seaport, the event gathered leading experts in heart failure innovation. The studies provide critical insights using Daxor’s Blood Volume Analysis (BVA) technology, highlighting the superior accuracy for fluid measurement by BVA compared to the limited accuracy of pulmonary artery pressure monitoring, while also unveiling new findings on diuretic therapy and its implications for enhanced treatment outcomes.
Key points:
- Duke study findings:
- No correlation between pulmonary artery pressure readings and actual blood volume as measured by BVA, illustrating the benefit of BVA for HF volume care.
- Challenges industry assumptions about pressure monitoring as a useful proxy for volume.
- Suggests current monitoring methods may miss critical patient information.
- Yale research highlights:
- A 5-year study using BVA examined the diuretic mechanism of action, showing the accuracy of BVA to detect shifts in volume as the gold standard.
- Revealed new insights into fluid removal process.
- Potential to improve treatment for millions on diuretic therapy.
- Key implications:
- BVA technology provides the most accurate fluid status assessment for this mechanistic study.
- Current home monitoring devices may have substantial limitations using proxies such as weight or pressure.
- New understanding of diuretic therapy could enhance treatment outcomes, with BVA providing evidence of effectiveness and utility for researchers in this field.
"These studies represent a paradigm shift in how we manage heart failure patients," says John L. Jefferies, MD, MPH, MBA, Daxor’s Chief Medical Officer. "For years, we've relied on pressure measurements as a proxy for fluid status, but the Duke study reveals this approach may be inadequate. Combined with Yale's breakthrough research on diuretics, it is becoming clear that direct blood volume measurement provides the missing piece we have needed. BVA gives us precise, actionable data about a patient's fluid status, allowing us to optimize therapy in ways we simply could not before.”
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
